BOSTON--(BUSINESS WIRE)--binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced that Jeff Luber, Chief Executive Officer of binx health, will present a company overview presentation at William Blair’s Innovator Series: Life Science Tools and Diagnostics on December 13th, 2022. The presentation will be followed by a Q&A session led by William Blair’s Research team.
A link to the recording will be available following the presentation in the News section of the binx health website. The conference highlights exciting private companies in the Life Science Tools and Diagnostics sectors.
About binx health
binx is a healthcare technology and women’s healthcare company that is leading the way to accessible routine testing by partnering with primary care, public health, retail health, universities, and leaders in HIV prevention and sexual health to reach underserved populations and impede the spread of sexually transmitted infections. The Company’s omnichannel platform is the only healthcare delivery model designed to reach people in-clinic and remotely with novel access modalities focused on the patient. binx is paving the way to improve population health issues at scale in partnership with those on the front lines of care. The Company’s dual-care offerings include the binx io, the first ever FDA-cleared, CLIA-waived, point-of-care chlamydia and gonorrhea test for males and females providing central lab performance results in about thirty minutes, and binx everywhere, a physician-mediated, secure, and highly configurable technology platform that integrates self-collection with high-quality laboratory testing and follow-up. binx’s proprietary platforms enable organizations to broaden access to care, promote health equity, and connect all key stakeholders of healthcare delivery in a seamless, evidenced-based manner that engenders consumer delight.
For more information, please visit www.mybinxhealth.com or follow binx health on LinkedIn.
binx everywhere may not be available in geographies outside of the US.